Open: 26.13 Close: 26.44 Change: 0.31

Today's Summary

Pfizer CEO Albert Bourla says he used extreme team-motivating tactics to meet impossible deadlines during the COVID-19 pandemic. Pfizer is transitioning from pandemic-reliant to pipeline-driven growth stock. The coming year will be important in determining whether Pfizer can move from recovery into sustained expansion. Pfizer is not likely to bring out a new blockbuster drug to offset the hit from its impending patent cliffs. History suggests that Pfizer will survive and thrive over the long term, even if there is a mismatch between new drugs and patent expirations in the short term.